Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 30 clinical trials
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.

cytotoxic chemotherapy
blood transfusion
neutrophil count
shortening fraction
monoclonal antibodies
  • 8 views
  • 13 Jun, 2022
  • 3 locations
OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer

modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating

  • 0 views
  • 10 Aug, 2022
  • 1 location
OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer

gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

  • 0 views
  • 22 Jul, 2022
  • 1 location
GM-CSF Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery

This study will examine whether the application of GM-CSF, fosfomycin and metronidazole locally in the pouch is safe and effective in the treatment of pouchitis for patients with ulcerative colitis, and whether treatment changes the microbiome of the pouch.

  • 0 views
  • 20 Sep, 2021
  • 1 location
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a

high-risk neuroblastoma
hu3f8
monoclonal antibodies
bone marrow procedure
colony stimulating factor
  • 159 views
  • 23 Mar, 2022
  • 23 locations
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided …

cancer
bilateral oophorectomy
vasectomy
anemia
  • 29 views
  • 28 Jul, 2022
  • 136 locations
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

This is a single-arm, uncontrolled, international, multi-center, clinical,phase 2 trial, in patients ≥ 12 months of age with high-risk neuroblastoma in first remission. 120 patients will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin.

high-risk neuroblastoma
isotretinoin
colony stimulating factor
  • 0 views
  • 22 Mar, 2022
  • 4 locations
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours

The purpose of this study is to determine whether radiotherapy (RT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment

chemotherapy regimen
serum pregnancy test
metastasis
neutrophil count
  • 0 views
  • 13 Jun, 2022
  • 1 location
Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma

) trastuzumab, as well as to evaluate toxicity of intrathecal trastuzumab in combination with subcutaneous (subQ) Granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with relapsed PFEPN

  • 1 views
  • 25 Feb, 2022
  • 1 location
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF

EGFR
cancer
bone marrow procedure
colony stimulating factor
high-risk neuroblastoma
  • 0 views
  • 08 Jul, 2022
  • 1 location